Samuel Klempner

67PUBLICATIONS
448CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersEconometric and statistical methodsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (67)

|Mar 23, 2026
The Pan-Tumor Landscape of Gene Amplifications and Copy Number Amplification Ratio for Established and Emerging Clinical Targets.

Jessica K Lee, Julia C F Quintanilha, Kuei-Ting Chen

|Mar 17, 2026
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.

Kohei Shitara, Hirokazu Shoji, Nicola Fazio

|Mar 11, 2026
Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics.

Joan Choo, Amalya Sargsyan, Vahe Khachatryan

|Mar 05, 2026
Reply to: Quality of Chemoradiotherapy in Esophageal Adenocarcinoma Matters.

Matthew R Strickland, Samuel J Klempner, Theodore S Hong

|Mar 02, 2026
Claudin proteins as emerging therapeutic targets for solid tumours.

Antonio Saviano, Alberto Toso, Samuel J Klempner

|Feb 06, 2026
Author Correction: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B.

Keun-Wook Lee, Devalingam Mahalingam, Byoung Yong Shim

Pageof 12

Frequent Collaborators

8 joint publications

Taehyang Lee

7 joint publications

Matthew Strickland

7 joint publications

Seung Tae Kim

6 joint publications

Jeeyun Lee